Oral Minoxidil vs Spironolactone: Long-Term Durability of Response

Oral minoxidil (an off-label, low-dose repurposing of the oral antihypertensive minoxidil, brand name Loniten) and spironolactone (an aldosterone antagonist marketed as Aldactone, also used off-label for hair loss and acne) are two of the most commonly prescribed systemic options for androgenetic and female pattern hair loss, and spironolactone is additionally used for hormonal acne in women. Neither drug is FDA-approved for hair loss; both uses discussed here are off-label. The two drugs work through different mechanisms, are not interchangeable by sex, and neither one produces a lasting cure once stopped.

The useful question is not which drug "works better" but which mechanism matches the patient's biology, and for how long treatment must continue. Minoxidil prolongs the hair growth phase and increases follicular blood flow without correcting androgen-driven miniaturization, so it must be taken indefinitely to sustain gains and is appropriate for men and women alike. Spironolactone blocks androgen receptor activity, which is only a relevant mechanism in women, and appears to produce more durable acne control than hair regrowth. In both drugs, discontinuation reliably leads to reversal of benefit within several months; this is a treat-to-maintain model, not a cure.

What This Article Can and Cannot Tell You

This comparison relies on published trial and cohort data referenced in dermatology literature, FDA drug labeling, and general clinical practice patterns. Several specific figures that circulated in earlier drafts of this topic (exact percentages tied to named authors and specific PubMed identifiers) could not be independently verified against the primary literature during this review and have been removed or converted to general, appropriately hedged statements. Where a precise number is retained, it is described as coming from "a study" or "a cohort" rather than attached to an unverified citation. Readers and clinicians who need exact effect sizes for a treatment decision should pull the primary paper directly rather than relying on secondhand summaries, including this one.

How Each Drug Works, and Why That Predicts Durability

Oral minoxidil is a potassium-channel opener. It prolongs the anagen (growth) phase of the hair cycle and increases blood flow to the follicle. It does not reduce dihydrotestosterone (DHT) activity or otherwise interrupt the androgen-driven miniaturization process that underlies androgenetic and female pattern hair loss. Because the underlying hormonal driver is untouched, the drug supports the follicle rather than correcting the disease process, which is why continuous dosing is generally required to sustain benefit.

Spironolactone is an aldosterone antagonist that also competitively blocks androgen receptors, lowering effective androgen signaling at the follicle and at sebaceous glands. This is a mechanism relevant to acne and to androgen-driven hair loss in women; it has no comparable role in men, where blocking androgen receptors at hair-loss-effective doses produces feminizing side effects instead of benefit.

Two Different Meanings of "Durability"

Durability in this context can mean two different things, and confusing them leads to overconfident claims:

• On-treatment durability: does the drug keep working at 12, 24, or 48 months without a plateau or loss of effect while the patient continues to take it?
• Off-treatment durability: does any benefit persist after the drug is stopped?

Available evidence for both drugs supports reasonably good on-treatment durability across the horizons most patients care about (roughly one to two years), though few studies extend meaningfully beyond that. Off-treatment durability is poor for both drugs: published reports and general clinical experience describe hair shedding resuming within roughly three to six months of stopping either agent, and acne recurrence after stopping spironolactone within a similar or shorter window. This is the single most important expectation-setting fact for patients starting either drug.

Oral Minoxidil: What the Evidence Supports

Low-dose oral minoxidil (roughly 0.25 to 5 mg/day, with lower doses more common in women) has an expanding observational and small-trial evidence base for androgenetic and female pattern hair loss. Reported patterns across published cohorts include:

• Visible improvement in hair density typically becomes apparent by three to six months of continuous use.
• Cohort follow-up out to about two years has generally shown maintained improvement in a majority of patients who remain on therapy without dose escalation, though exact response proportions vary by study population and measurement method and should not be treated as fixed figures.
• No clear pattern of pharmacological tachyphylaxis (loss of effect over time while still on the drug) has been reported in the published follow-up periods available, which mostly run one to two years.
• Side effects that tend to worsen with dose and duration rather than resolve include hypertrichosis (excess hair growth on the face and body, more noticeable in women) and fluid retention or lower-extremity edema, the latter more common at doses above roughly 2.5 mg/day.

A randomized comparison of oral versus topical minoxidil in men has been reported in the dermatology literature, showing outcomes favoring the oral route on some measures without reaching clear statistical significance in that trial; the exact effect size requires verification against the original paper before being cited as a clinical fact.

Spironolactone: What the Evidence Supports

Spironolactone's evidence base for acne is older and more established than its evidence base for hair loss.

For hormonal acne, published cohort data describe a majority of women maintaining meaningful lesion reduction well beyond one year of continued therapy, with a substantial minority able to taper off while remaining clear and others requiring ongoing treatment to stay controlled. An often-cited long-term follow-up study of women with persistent acne on spironolactone reported sustained benefit at several years of follow-up in most patients who stayed on the drug; the exact proportions attributed to this study in earlier versions of this article could not be verified against the primary source in this review and are presented here only in general terms. Anyone relying on precise long-term retention numbers should verify them against the original publication rather than a secondary citation.

For hair loss, the timeline is longer and the response is more variable than for acne. Reduced shedding is commonly reported within three to six months, but visible regrowth on standardized photography typically takes six to eighteen months to become apparent, and a meaningful share of women who experience reduced shedding do not show measurable regrowth on that timeline. Response appears more consistent in women with clinical or laboratory evidence of hyperandrogenism (for example, PCOS-associated hair loss) than in women without those markers, which is consistent with the drug's androgen-receptor mechanism.

Regulatory and Safety Anchor

Spironolactone's FDA label carries a hyperkalemia warning and recommends renal function and potassium monitoring, particularly relevant in women over 45 or with reduced kidney function (FDA spironolactone label). Standard practice, not a fixed FDA requirement, is to check potassium and creatinine at baseline, four to eight weeks after starting or changing dose, and periodically thereafter in stable patients; the exact interval should be individualized by the prescriber. Menstrual irregularity is a common dose-dependent side effect at doses above roughly 100 mg/day and is a frequent reason for dose reduction or discontinuation.

Oral minoxidil's parent drug label was originally approved for resistant hypertension, and the cardiovascular precautions in that label (relevant to fluid retention, tachycardia, and pericardial effusion at higher doses) are the basis for cardiovascular screening recommendations even at the much lower doses used for hair loss, per the drug's original FDA labeling.

Decision Table: Matching the Drug to the Patient

This table reflects general patterns described in the dermatology literature and standard prescribing practice, not a head-to-head randomized trial. No trial directly comparing oral minoxidil against spironolactone for durability as a primary endpoint has been identified for this review.

Combining the Two Drugs

Because the two drugs act on different biological targets, combination use is mechanistically plausible and is used in practice for patients with an incomplete response to either drug alone. Small pilot studies have reported additional hair density improvement when oral minoxidil is added to spironolactone in women with a partial response to spironolactone monotherapy, though sample sizes in this literature are small and results should be treated as preliminary rather than definitive.

Combination therapy is not appropriate for everyone. Patients with baseline low blood pressure, significantly reduced kidney function, or a history of cardiac arrhythmia should not start combination therapy without specialist input, since both drugs can lower blood pressure and spironolactone affects electrolytes. Spironolactone is contraindicated in pregnancy, and oral minoxidil also carries pregnancy-related precautions, so reliable contraception is required for women of childbearing potential on either drug alone or combined.

Switching From One Drug to the Other

Switching from oral minoxidil to spironolactone is most often considered in premenopausal women with a partial minoxidil response who also have signs of androgen excess or want a single drug to address both hair loss and acne.

A commonly described approach in clinical practice, though not standardized by a formal guideline, is a brief overlap period: starting spironolactone at a low dose while continuing oral minoxidil, then tapering minoxidil over one to two weeks once spironolactone is established, and titrating spironolactone upward over the following weeks based on tolerability and lab monitoring. Stopping oral minoxidil abruptly without overlap has been associated with a temporary increase in shedding in some reports, which is consistent with minoxidil's mechanism (an abrupt end to prolonged anagen phase can synchronize follicles into telogen).

Switching does not make sense for men, since spironolactone is not a hair-loss option for them, and it offers limited additional benefit for postmenopausal women without hyperandrogenic markers, who are generally better served by continuing oral minoxidil.

Stopping and Restarting

Both drugs can be stopped and restarted without evidence of pharmacological tolerance building up. Patients who pause for surgery, pregnancy planning, or coverage gaps typically see shedding resume within a matter of weeks to a few months and can generally restart at the prior dose, though restarting after a long gap (several months or more) is a reasonable point to recheck cardiovascular status (for minoxidil) or electrolytes (for spironolactone) rather than resuming blind.

What Is Established, What Is Plausible, and What Is Not Established

Established: Oral minoxidil and spironolactone are both used off-label for hair loss, with spironolactone additionally used off-label for hormonal acne in women. Spironolactone is not an appropriate hair-loss treatment for men at effective doses due to antiandrogenic side effects. Both drugs require ongoing use to sustain benefit, and stopping either one is followed by loss of benefit over a period of months rather than a permanent result. Spironolactone carries an FDA-labeled hyperkalemia warning; minoxidil's cardiovascular precautions derive from its original hypertension-dose labeling.

Plausible but not firmly established: That spironolactone's durability, once started, is meaningfully better than oral minoxidil's for hair loss specifically in women with confirmed hyperandrogenism. That combining the two drugs produces durability benefits beyond what either produces alone, beyond what small pilot data suggest. That a specific overlap protocol (versus a shorter or longer one) is the optimal way to switch between the drugs.

Not established: Any head-to-head randomized trial comparing oral minoxidil against spironolactone with durability as the primary outcome. Precise long-term (beyond two years) response percentages for either drug in the general population, since most published follow-up is limited to roughly one to two years. Any claim that either drug's benefits persist beyond the treatment period.

When to Seek Urgent or Specialist Care

Sudden patchy hair loss, hair loss with scalp scarring, pain, or scaling, or hair loss accompanied by other new symptoms such as unexplained weight change or fatigue warrants evaluation before starting either drug, since these can indicate a different underlying diagnosis. On either drug, new or worsening shortness of breath, significant swelling, chest pain, or palpitations warrants urgent medical evaluation rather than waiting for a routine follow-up. Muscle weakness, irregular heartbeat, or other symptoms of possible hyperkalemia on spironolactone should prompt an urgent potassium check.

References

1. FDA prescribing information, spironolactone (Aldactone). https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/012151s062lbl.pdf

A dedicated primary-literature search for this topic did not return verifiable results during this review. Several specific study citations, author names, sample sizes, and effect sizes present in an earlier draft of this article could not be confirmed against the primary literature and have been removed, generalized, or flagged above. Before this article is published, qualified medical and editorial review should re-verify any retained numeric claim against its original source and add correctly identified primary citations for the trial and cohort data referenced in general terms throughout.